Provided by Tiger Trade Technology Pte. Ltd.

ProQR Therapeutics NV

2.43
+0.09003.85%
Post-market: 2.39-0.0400-1.65%17:01 EDT
Volume:1.06M
Turnover:2.53M
Market Cap:342.92M
PE:-5.31
High:2.46
Open:2.35
Low:2.26
Close:2.34
52wk High:3.10
52wk Low:1.33
Shares:141.12M
Float Shares:101.18M
Volume Ratio:0.81
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4578
EPS(LYR):-0.4702
ROE:-57.40%
ROA:-19.76%
PB:3.70
PE(LYR):-5.17

Loading ...

ProQR Therapeutics prices 27.62M shares at $1.81 in registered direct offering

TIPRANKS
·
Jun 25

ProQR Therapeutics announces positive Phase 1 data for AX-0810

TIPRANKS
·
Jun 25

Proqr Prices $50 Million Follow-on Offering at $1.81 Per Share

Reuters
·
Jun 25

Proqr Therapeutics Nv - to Use Proceeds for Research, Clinical Development, and General Corporate Purposes

THOMSON REUTERS
·
Jun 25

Proqr Therapeutics Nv - Eli Lilly to Purchase 5.1 Mln Proqr Shares at $1.81/share for $9.2 Mln

THOMSON REUTERS
·
Jun 25

Proqr Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

THOMSON REUTERS
·
Jun 25

Proqr Reports Phase 1 Target Engagement for Ax-0810 RNA Editing Drug in Healthy Volunteers

Reuters
·
Jun 25

Proqr Therapeutics Nv - Phase 2 Program Expected to Start Mid-2027 with Interim Data by Mid-2028

THOMSON REUTERS
·
Jun 25

Proqr Therapeutics Nv - Ax-810 Shows Favorable Safety Profile and Eight-week Half-life

THOMSON REUTERS
·
Jun 25

Proqr Announces Positive Phase 1 Target Engagement Data for Ax-0810, Establishing First Clinical Validation of the Axiomer Rna Editing Platform

THOMSON REUTERS
·
Jun 25

Proqr Therapeutics Nv - Ax-422 Cta Filing for Mps1 Expected Early 2027 with Initial Data First Half 2027

THOMSON REUTERS
·
Jun 25

Proqr Therapeutics Nv - Ax-2911 First-in-human Iit in China Expected First Half 2027

THOMSON REUTERS
·
Jun 25

ProQR Therapeutics holds annual shareholder meeting, backs 2025 accounts 99.7%

Reuters
·
Jun 03

ProQR Therapeutics files Form 3 for director Hinsch Gylvin Lykke

Reuters
·
Jun 03

Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), ProQR (PRQR) and OptimizeRx (OPRX)

TIPRANKS
·
May 13

ProQR Therapeutics Q1 revenue falls and misses estimates

Reuters
·
May 12

ProQR Q1 FY26 net loss widens to €13.38 million; revenue drops to €2.03 million

Reuters
·
May 12

BRIEF-ProQR Therapeutics Q1 EPS EUR -0.13

Reuters
·
May 12

ProQR Therapeutics Q1 Revenue EUR 2.033 Million VS. Ibes Estimate EUR 5.25 Million

THOMSON REUTERS
·
May 12

ProQR Therapeutics Q1 Net Income EUR -13.383 Million

THOMSON REUTERS
·
May 12